[go: up one dir, main page]

WO2009001940A1 - ペリオスチンのＥｘｏｎ－１７部位によりコードされるペプチドに対する抗体を含む癌治療剤 - Google Patents

ペリオスチンのＥｘｏｎ－１７部位によりコードされるペプチドに対する抗体を含む癌治療剤 Download PDF

Info

Publication number
WO2009001940A1
WO2009001940A1 PCT/JP2008/061768 JP2008061768W WO2009001940A1 WO 2009001940 A1 WO2009001940 A1 WO 2009001940A1 JP 2008061768 W JP2008061768 W JP 2008061768W WO 2009001940 A1 WO2009001940 A1 WO 2009001940A1
Authority
WO
WIPO (PCT)
Prior art keywords
periostin
exon
cancer
antibody against
containing antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/061768
Other languages
English (en)
French (fr)
Inventor
Yoshiaki Taniyama
Ryuichi Morishita
Naruto Katsuragi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asubio Pharma Co Ltd
University of Osaka NUC
Original Assignee
Osaka University NUC
Asubio Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC, Asubio Pharma Co Ltd filed Critical Osaka University NUC
Priority to EP08777680.3A priority Critical patent/EP2168599B1/en
Priority to CN2008800210040A priority patent/CN101888855A/zh
Priority to JP2009520653A priority patent/JP5238942B2/ja
Priority to CA2690888A priority patent/CA2690888C/en
Publication of WO2009001940A1 publication Critical patent/WO2009001940A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G01N33/5758—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　本発明は、ペリオスチンのＥｘｏｎ－１７によりコードされるペプチド領域に対する抗体を含む、癌治療用医薬組成物に関する。更に詳しくは、癌組織をはじめとして組織再構築の間質において特異的に発現する、抗細胞接着作用を有するペリオスチンのスプライシングバリアントを認識する抗ペリオスチン抗体を含む、癌治療用医薬組成物、または前記抗ペリオスチン抗体を用いた癌の診断方法および診断薬に関する。 　　
PCT/JP2008/061768 2007-06-27 2008-06-27 ペリオスチンのＥｘｏｎ－１７部位によりコードされるペプチドに対する抗体を含む癌治療剤 Ceased WO2009001940A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP08777680.3A EP2168599B1 (en) 2007-06-27 2008-06-27 Cancer remedy containing antibody against peptide encoded by exon-17 of periostin
CN2008800210040A CN101888855A (zh) 2007-06-27 2008-06-27 含有由抗骨膜素的外显子-17编码的肽的抗体的癌症治疗剂
JP2009520653A JP5238942B2 (ja) 2007-06-27 2008-06-27 ペリオスチンのＥｘｏｎ−１７部位によりコードされるペプチドに対する抗体を含む癌治療剤
CA2690888A CA2690888C (en) 2007-06-27 2008-06-27 Cancer therapeutic composition comprising antibody against peptide encoded by exon-17 site of periostin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-169494 2007-06-27
JP2007169494 2007-06-27
JP2008033827 2008-02-14
JP2008-033827 2008-02-14

Publications (1)

Publication Number Publication Date
WO2009001940A1 true WO2009001940A1 (ja) 2008-12-31

Family

ID=40185749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/061768 Ceased WO2009001940A1 (ja) 2007-06-27 2008-06-27 ペリオスチンのＥｘｏｎ－１７部位によりコードされるペプチドに対する抗体を含む癌治療剤

Country Status (6)

Country Link
EP (1) EP2168599B1 (ja)
JP (1) JP5238942B2 (ja)
KR (1) KR101560843B1 (ja)
CN (1) CN101888855A (ja)
CA (1) CA2690888C (ja)
WO (1) WO2009001940A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013038696A1 (ja) 2011-09-15 2013-03-21 国立大学法人名古屋大学 胸膜中皮腫患者の早期発見のための分子マーカー及びその発現解析方法
US9684000B2 (en) 2010-12-16 2017-06-20 Genentech, Inc. Diagnosis and treatments relating to TH2 inhibition
US10227396B2 (en) 2013-03-08 2019-03-12 Osaka University Antibody against peptide encoded by Exon-21 of periostin and pharmaceutical composition for preventing or treating inflammation-associated diseases containing the same
WO2019146621A1 (ja) * 2018-01-25 2019-08-01 国立大学法人大阪大学 ペリオスチンの発現量増加またはスプライシングバリアントの変化を伴う疾患の治療用医薬組成物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011024114A1 (en) * 2009-08-25 2011-03-03 Ecole Polytechnique Federale De Lausanne (Epfl) Targeting extracellular matrix molecules for the treatment of cancer
CN101773671A (zh) * 2010-03-04 2010-07-14 北京大学第三医院 Periostin基因的shRNA在制备抑制肿瘤的药物中的应用
FR2992221A1 (fr) 2012-06-22 2013-12-27 Centre Nat Rech Scient Modification des effets immunomodulateurs des cellules
CN106164675B (zh) 2014-02-07 2019-04-23 免疫医疗有限责任公司 检测人类骨膜蛋白的新型测定
KR102127478B1 (ko) * 2019-09-06 2020-07-08 연세대학교 산학협력단 난소암에 대한 정보 제공 방법 및 이를 이용한 키트
WO2023036305A1 (zh) * 2021-09-13 2023-03-16 沈阳眼产业技术研究院有限公司 抗periostin人源化单克隆抗体及其制备方法与应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04502408A (ja) 1988-12-28 1992-05-07 プロテイン　デザイン　ラブス，インコーポレイティド ＩＬ―２レセプターのｐ５５　Ｔａｃタンパク質に特異的なキメラ免疫グロブリン
JPH05268982A (ja) 1992-03-27 1993-10-19 Hoechst Japan Ltd 骨形成作用を有する新規な蛋白質およびその製造法
JPH06500233A (ja) 1990-08-29 1994-01-13 ジェンファーム　インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO2002020055A1 (fr) 2000-09-08 2002-03-14 Daiichi Suntory Pharma Co., Ltd. Médicaments contre les défaillances cardiaques
JP2005500059A (ja) * 2001-08-13 2005-01-06 ダナ−ファーバー キャンサー インスティテュート インク． ペリオスチンに基づく診断アッセイ法
WO2005019471A2 (en) 2003-08-13 2005-03-03 Temple University Of The Commonwealth System Of Higher Education Periostin-like factor: compositions and methods for making and using the same
WO2007077934A1 (ja) * 2005-12-28 2007-07-12 Asubio Pharma Co., Ltd. 抗ペリオスチン抗体およびそれを含有するペリオスチンが関与する疾患の予防または治療用医薬組成物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04502408A (ja) 1988-12-28 1992-05-07 プロテイン　デザイン　ラブス，インコーポレイティド ＩＬ―２レセプターのｐ５５　Ｔａｃタンパク質に特異的なキメラ免疫グロブリン
JPH06500233A (ja) 1990-08-29 1994-01-13 ジェンファーム　インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
JPH05268982A (ja) 1992-03-27 1993-10-19 Hoechst Japan Ltd 骨形成作用を有する新規な蛋白質およびその製造法
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO2002020055A1 (fr) 2000-09-08 2002-03-14 Daiichi Suntory Pharma Co., Ltd. Médicaments contre les défaillances cardiaques
JP2005500059A (ja) * 2001-08-13 2005-01-06 ダナ−ファーバー キャンサー インスティテュート インク． ペリオスチンに基づく診断アッセイ法
WO2005019471A2 (en) 2003-08-13 2005-03-03 Temple University Of The Commonwealth System Of Higher Education Periostin-like factor: compositions and methods for making and using the same
WO2007077934A1 (ja) * 2005-12-28 2007-07-12 Asubio Pharma Co., Ltd. 抗ペリオスチン抗体およびそれを含有するペリオスチンが関与する疾患の予防または治療用医薬組成物

Non-Patent Citations (46)

* Cited by examiner, † Cited by third party
Title
BAO S. ET AL., CANCER CELL, vol. 5, no. 4, 2004, pages 329 - 39
BARIL P. ET AL., ONCOGENE, vol. 26, no. 14, 2007, pages 2082 - 94
BEGENT ET AL., BR. J. CANCER, vol. 62, 1990, pages 487
CHOTHIA C. ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 17
CURR. TOP. MICROBIOL. IMMUNOL., vol. 81, 1978, pages 1 - 7
ERKAN M. ET AL., GASTROENTEROLOGY, vol. 132, no. 4, 2007, pages 1447 - 64
G. KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 - 7
GILLAN L. ET AL., CANCER RES., vol. 62, 2002, pages 5358 - 64
GONZALEZ HE. ET AL., ARCH OTOLARYNGOL HEAD NECK SURG., vol. 129, 2003, pages 754 - 9
GREEN LL ET AL., NATURE GENETICS, vol. 7, 1994, pages 13 - 21
GRIGORIADIS A. ET AL., BREAST CANCER RES, vol. 8, no. 5, 2006
HANAHAN D. ET AL., CELL, vol. 86, 1996, pages 353 - 364
HORIUCHI K. ET AL., J. BONE MINER. RES., vol. 14, 1999, pages 1239 - 49
KABATT ET AL.: "SEQUENCES OF IMMUNOLOGICAL INTEREST", NIH PUBLICATION, NO. 91-3242
KATSURAGI N. ET AL., CIRCULATION, vol. 110, 2004, pages 1806 - 13
KIM C.-J. ET AL.: "Periostin no alternative splicing variants to Akuseika Oyobi Shijun.Ten-i tono Kanren", ANNUAL MEETING OF THE JAPAN CANCER ASSOCIATION KIJI, vol. 65TH, 2006, pages 302 + ABSTR. NO. P-572 *
KIM CJ ET AL., INT J CANCER, vol. 117, no. 1, 2005, pages 51 - 8
KUDO Y. ET AL., CANCER RES, vol. 66, no. 14, 2006, pages 6928 - 35
LINDNER V. ET AL., ARTERIOSCLER THROMB VASE BID., vol. 25, 2005, pages 77 - 83
LIOTTA LA. ET AL., CELL, vol. 64, 1991, pages 327 - 336
LIOTTA LA. ET AL., PROC. NATL. ACAD. SCI., vol. 83, 1986, pages 3302 - 3306
LITVIN J. ET AL., J CELL BIOCHEM., vol. 92, 2004, pages 1044 - 61
MENDEZ MJ ET AL., NATURE GENETICS, vol. 15, 1997, pages 146 - 56
MORRISON SL. ET AL., PROC NATL ACAD SCI USA., vol. 81, 1984, pages 6851 - 5
NATURE, vol. 276, 1978, pages 269
NIKKEI, SCIENCE, 1995, pages 40 - 50
NILS LONBERG ET AL., NATURE, vol. 368, 1994, pages 856 - 9
OLKMAN J., SEMIN. CANCER BIOL, vol. 3, 1992, pages 65 - 71
OSHIMA A ET AL., J CELL BIOCHEM, vol. 86, no. 4, 2002, pages 792 - 804
PETER T ET AL., NATURE, vol. 321, 1986, pages 522 - 5
PETERS DG. ET AL., STROKE, vol. 32, 2001, pages 1036 - 42
SASAKI H. ET AL., AM J OBSTET GYNECOL., vol. 186, 2002, pages 103 - 8
SASAKI H. ET AL., BREAST CANCER RES TREAT., vol. 77, 2003, pages 245 - 52
SASAKI H. ET AL., CANCER LETT., vol. 72, no. 1, 2001, pages 37 - 42
SASAKI H. ET AL., CANCER, vol. 92, no. 4, 2001, pages 843 - 8
SCHROFF RW. ET AL., CANCER RES., vol. 45, 1985, pages 879 - 85
See also references of EP2168599A4
SHAO R. ET AL., MOL CELL BIOL., vol. 24, 2004, pages 3992 - 4003
SIRIWARDENA BS. ET AL., BR J CANCER, vol. 95, no. 10, 2006, pages 1396 - 403
TAI I.T. ET AL.: "Periostin induction in tumor cell line explants and inhibition of in vitro cell growth by anti-periostin antibodies", CARCINOGENESIS, vol. 26, no. 5, 2005, pages 908 - 915, XP008127943 *
TAI IT. ET AL., CARCINOGENESIS, vol. 26, 2005, pages 908 - 15
TAKESHITA S. ET AL., BIOCHEM J, vol. 294, 1993, pages 271 - 8
THIERY JP. ET AL., NAT MED., vol. 10, no. 8, 2004, pages 777 - 8
WANG D. ET AL., HYPERTENSION, vol. 42, 2003, pages 88 - 95
YAN W. ET AL., J. BIOL. CHEM., vol. 281, no. 28, 2006, pages 19700 - 8
YANG J ET AL., CELL, vol. 117, no. 7, 2004, pages 927 - 39

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9684000B2 (en) 2010-12-16 2017-06-20 Genentech, Inc. Diagnosis and treatments relating to TH2 inhibition
US9995755B2 (en) 2010-12-16 2018-06-12 Genentech, Inc. Diagnosis and treatments relating to TH2 inhibition
US11226341B2 (en) 2010-12-16 2022-01-18 Genentech, Inc. Method of treating asthma using an IL-13 antibody
WO2013038696A1 (ja) 2011-09-15 2013-03-21 国立大学法人名古屋大学 胸膜中皮腫患者の早期発見のための分子マーカー及びその発現解析方法
US10227396B2 (en) 2013-03-08 2019-03-12 Osaka University Antibody against peptide encoded by Exon-21 of periostin and pharmaceutical composition for preventing or treating inflammation-associated diseases containing the same
WO2019146621A1 (ja) * 2018-01-25 2019-08-01 国立大学法人大阪大学 ペリオスチンの発現量増加またはスプライシングバリアントの変化を伴う疾患の治療用医薬組成物
JPWO2019146621A1 (ja) * 2018-01-25 2021-01-07 国立大学法人大阪大学 ペリオスチンの発現量増加またはスプライシングバリアントの変化を伴う疾患の治療用医薬組成物
JP7261482B2 (ja) 2018-01-25 2023-04-20 国立大学法人大阪大学 ペリオスチンの発現量増加またはスプライシングバリアントの変化を伴う疾患の治療用医薬組成物
US12227743B2 (en) 2018-01-25 2025-02-18 Osaka University Pharmaceutical composition for treatment of diseases associated with upregulated periostin expression or periostin splice variant switching

Also Published As

Publication number Publication date
KR20100023869A (ko) 2010-03-04
EP2168599B1 (en) 2016-08-10
CA2690888C (en) 2016-02-09
EP2168599A1 (en) 2010-03-31
JP5238942B2 (ja) 2013-07-17
EP2168599A4 (en) 2013-02-27
KR101560843B1 (ko) 2015-10-15
CA2690888A1 (en) 2008-12-31
CN101888855A (zh) 2010-11-17
JPWO2009001940A1 (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
WO2009001940A1 (ja) ペリオスチンのＥｘｏｎ－１７部位によりコードされるペプチドに対する抗体を含む癌治療剤
WO2009040420A3 (en) Use of a monoterpene to increase tissue repair
WO2007089454A3 (en) Methods for enhancing skin treatments
WO2010062581A3 (en) A botanical composition for enhanced skin repair and uses thereof
WO2009158128A3 (en) Dressing assemblies for wound treatment using reduced pressure
WO2009075882A3 (en) Impaired wound healing compositions and treatments
WO2008036238A3 (en) Use of lxr modulators for the prevention and treatment of skin aging
WO2010065435A3 (en) System and method for mechanical closure of wounds
WO2010054167A3 (en) Limited proteolysis of cd2ap and progression of renal disease
WO2009067605A3 (en) Preparations, methods and kits useful for treatment of cough
WO2008143954A3 (en) Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
EA200801717A1 (ru) Композиция местного применения по уходу за кожей, продукт на ее основе и способ лечения
WO2010030728A3 (en) Devices and systems for delivery of therapeutic agents to body lumens
WO2008012555A3 (en) Epitope reduction therapy
EP2500044A3 (en) Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
WO2007117580A3 (en) Apparatus and method for skin treatment with compression and decompression
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2008139122A3 (fr) Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
WO2009154840A3 (en) Compositions and methods using stem cells in cutaneous wound healing
WO2009074735A8 (fr) Utilisation d'un nouvel agent naturel dans des compositions cosmetiques
WO2009109911A8 (en) Methods of treating chronic pain
WO2006105450A3 (en) Compositions and methods for treating acne
WO2008033804A3 (en) Quantum dot barcode structures and uses thereof
WO2008151749A3 (de) Aktivierbare diagnostische und therapeutische verbindung
WO2010054377A3 (en) Fully human antibodies against n-cadherin

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880021004.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08777680

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009520653

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2690888

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 20097026078

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2008777680

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008777680

Country of ref document: EP